Natural history of chronic hepatitis B: What exactly has REVEAL Revealed?

Liver International

Volumn 32, Issue 9, 2012, Pages 1333-1341

  Iloeje, Uchenna H ^a   Yang, Hwai I ^b,c   Chen, Chien Jen ^d,e  

^a BRISTOL MYERS SQUIBB   (United States)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d GENOMICS RESEARCH CENTER   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

CHB natural history; Chronic hepatitis B; Hepatitis B disease progression; REVEAL

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; VIRUS DNA;

CANCER RISK; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; MEDICAL HISTORY; MORTALITY; NOMOGRAM; PROMOTER REGION; REVIEW; VIRUS LOAD;

ANTIGENS, VIRAL; CARCINOMA, HEPATOCELLULAR; CARRIER STATE; COMORBIDITY; DISEASE PROGRESSION; DNA, VIRAL; GENOTYPE; HEPATITIS B ANTIBODIES; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MUTATION; NOMOGRAMS; PROSPECTIVE STUDIES; SEROEPIDEMIOLOGIC STUDIES; SURVIVAL RATE; TAIWAN; VIRAL LOAD;

EID: 84865797226     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2012.02805.x     Document Type: Review

References (57)

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11: 97-107.
2. World Health Organization. Fact Sheet: Hepatitis B. 2008.http://www.who.int/mediacentre/factsheets/fs204/en/index.html.Accessed 9 June 2011.
3. Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997; 336: 1855-9.
4. Chang MH, You SL, Chen CJ, et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst 2009; 101: 1348-55.
5. Kao JH, Hsu HM, Shau WY, Chang MH, Chen DS. Universal hepatitis B vaccination and the decreased mortality from fulminant hepatitis in infants in Taiwan. J Pediatr 2001; 139: 349-52.
6. Chen CJ, Wang LY, Yu MW. Epidemiology of hepatitis B virus infection in the Asia-Pacific region. J Gastroenterol Hepatol 2000; 15(Suppl.): E3-6.
7. Custer B, Sullivan SD, Hazlet TK, et al. Global epidemiology of hepatitis B virus. J Clin Gastroenterol 2004; 38: S158-68.
8. Chen CJ, Iloeje UH, Yang HI. Long-Term Outcomes in Hepatitis B: the REVEAL-HBV Study. Clin Liver Dis 2007; 11: 797-816.
9. Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337: 1733-45.
10. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009; 373: 582-92.
11. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2001; 34: 1225-41.
12. You SL, Yang HI, Chen CJ. Seropositivity of hepatitis B e antigen and hepatocellular carcinoma. Ann Med 2004; 36: 215-24.
13. Yang HI, Lu SN, Liaw YF, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002; 347: 168-74.
14. Chen CJ, Yang HI, You SL. Hepatitis B e antigen and the risk of hepatocellular carcinoma (authors reply). N Engl J Med 2002; 347: 1722.
15. Lin DY, Sheen IS, Chiu CT, et al. Ultrasonographic changes of early liver cirrhosis in chronic hepatitis B: a longitudinal study. J Clin Ultrasound 1993; 21: 303-8.
16. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73.
17. Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678-86.
18. Iloeje UH, Yang HI, Jen CL, et al. Risk and predictors of mortality associated with chronic hepatitis B infection. Clin Gastroenterol Hepatol 2007; 5: 921-31.
19. Yang HI, Yeh SH, Chen PJ, et al. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: 1134-43.
20. Yang HI, Sherman M, Su J, et al. Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Clin Oncol 2010; 28: 2437-44.
21. Yang HI, Yuen MF, Chan HL, et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol 2011; 12: 568-74.
22. Han KH, Ahn SH. How to predict HCC development in patients with chronic B viral liver disease? Intervirology 2005; 48: 23-8.
23. Wong VW, Chan SL, Mo F, et al. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol 2010; 28: 1660-5.
24. Yuen MF, Tanaka Y, Fong DY, et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol 2009; 50: 80-8.
25. Liu J, Yang HI, Lee MH, et al. Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study. Gastroenterology 2010; 139: 474-82.
26. Sorrell MF, Belongia EA, Costa J, et al. National Institutes of Health consensus development conference statement: management of hepatitis B. Hepatology 2009; 49: S4-12.
27. Ahn SH, Park YN, Park JY, et al. Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance. J Hepatol 2005; 42: 188-94.
28. Arase Y, Ikeda K, Suzuki F, et al. Long-term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B. Am J Med 2006; 119: 71-16.
29. Chen YC, Sheen IS, Chu CM, Liaw YF. Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology 2002; 123: 1084-9.
30. Mommeja-Marin H, Mondou E, Blum MR, Rousseau F. Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. Hepatology 2003; 37: 1309-19.
31. Chen JD, Yang HI, Iloeje UH, et al. Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. Gastroenterology 2010; 138: 1747-54.
32. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000-summary of a workshop. Gastroenterology 2001; 120: 1828-53.
33. Iloeje UH, Yang HI, Jen CL, et al. Risk of pancreatic cancer in chronic hepatitis B virus infection: data from the REVEAL-HBV cohort study. Liver Int 2010; 30: 423-9.
34. Hoefs JC, Renner IG, Askhcavai M, Redeker AG. Hepatitis B surface antigen in pancreatic and biliary secretions. Gastroenterology 1980; 79: 191-4.
35. Chen CJ, Iloeje UH, Yang HI. Serum hepatitis B virus DNA as a predictor of the development of cirrhosis and hepatocellular carcinoma. Curr Hepatitis Rep 2007; 6: 9-16.
36. Chen CJ, Yang HI, Iloeje UH. Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology 2009; 49: S72-84.
37. Chen CJ, Yang HI. Natural history of chronic hepatitis B REVEALed. J Gastroenterol Hepatol 2011; 26: 628-38.
38. Chen DS, Hsu NH, Sung JL, et al. A mass vaccination program in Taiwan against hepatitis B virus infection in infants of hepatitis B surface antigen-carrier mothers. JAMA 1987; 257: 2597-603.
39. Chen CJ, Yang HI, Su J, et al. Serial monitoring of viral load and serum alanine aminotransferase level and the risk of hepatocellular carcinoma (HCC): R.E.V.E.A.L.-HBV study update [abstract 141]. J Hepatol 2008; 48: S61.
40. Chen CF, Yang HI, Iloeje UH, et al. Changes in serum HBV DNA level using a trajectory model to predict the risk of HCC in chronic hepatitis B patients: the R.E.V.E.A.L.-HBV Study (abstract). Hepatology 2007; 46: 639A.
41. Chen CF, Lee WC, Yang HI, et al. Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma. Gastroenterology 2011; 141: 1240-8.
42. Yang HI, Iloeje UH, Su J, et al. Association between HBV replication and serum ALT changes is not dependent on HBV genotype and mutants (abstract). Gastroenterology 2009; 136: A864.
43. Kumar M, Sarin SK, Hissar S, et al. Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT. Gastroenterology 2008; 134: 1376-84.
44. Lai M, Hyatt BJ, Nasser I, Curry M, Afdhal NH. The clinical significance of persistently normal ALT in chronic hepatitis B infection. J Hepatol 2007; 47: 760-7.
45. Kim HC, Nam CM, Jee SH, et al. Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. BMJ 2004; 328: 983.
46. Kim JH, Lee JH, Park SJ, et al. Factors associated with natural seroclearance of hepatitis B surface antigen and prognosis after seroclearance: a prospective follow-up study. Hepatogastroenterology 2008; 55: 578-81.
47. Tseng TC, Liu CJ, Su TH, et al. Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters. Gastroenterology 2011; 141: 517-25, 525
48. Liu J, Lee MH, Batrla-Utermann R, et al. Quantitative hepatitis B surface antigen levels are significant independent predictors of HBV DNA and HBsAg seroclearance in chronic hepatitis B (abstract). Hepatology 2011; 54: 480A-1A.
49. Hohenberger P. Detection of HBs-Ag in the pancreas in cases of pancreatic carcinoma. Hepatogastroenterology 1984; 31: 239-41.
50. Hohenberger P. [The pancreas as target organ for hepatitis B virus-immunohistological detection of HBsAg in pancreatic carcinoma and chronic pancreatitis]. Leber Magen Darm 1985; 15: 58-63.
51. Katakura Y, Yotsuyanagi H, Hashizume K, et al. Pancreatic involvement in chronic viral hepatitis. World J Gastroenterol 2005; 11: 3508-13.
52. Jain P, Nijhawan S. Acute viral hepatitis with pancreatitis: is it due to the viruses or sludge? Pancreatology 2007; 7: 544-5.
53. Dejean A, Lugassy C, Zafrani S, Tiollais P, Brechot C. Detection of hepatitis B virus DNA in pancreas, kidney and skin of two human carriers of the virus. J Gen Virol 1984; 65: 651-5.
54. Shimoda T, Shikata T, Karasawa T, et al. Light microscopic localization of hepatitis B virus antigens in the human pancreas. Possibility of multiplication of hepatitis B virus in the human pancreas. Gastroenterology 1981; 81: 998-1005.
55. Liaw YF. Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: a review. Hepatology 2011; 53: 2121-9.
56. Kamatani Y, Wattanapokayakit S, Ochi H, et al. A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. Nat Genet 2009; 41: 595-5.
57. Zhang H, Zhai Y, Hu Z, et al. Genome-wide association study identifies 1p36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers. Nat Genet 2010; 42: 755-8.